Complete response of sunitinib therapy for renal cell cancer recurrence in the native kidney after renal transplantation: a case report
書誌事項
- 公開日
- 2014-08-13
- DOI
-
- 10.1186/1756-0500-7-526
- 公開者
- Springer Science and Business Media LLC
説明
No case report has yet shown that sunitinib therapy for the postoperative recurrence of renal cancer in a native kidney after renal transplantation can achieve complete response (CR).A tumor was detected in the right native kidney of a 35-year-old Japanese male 10 years after renal transplantation. A tumor thrombus that reached the atrium was detected, which suggested cT3cN0M0. Because of the risk of perioperative complications, preoperative therapy with sunitinib was selected and 8 courses were administered. The size of the primary tumor was reduced by 33%, while that of the tumor thrombus was decreased by 39.5%. Right nephrectomy and removal of the tumor thrombus were then performed. Contrast-enhanced computed tomography (CT) four months after surgery suggested local relapse. Sunitinib was administered for 9 months, which led to complete response (CR).This study presented the case of sunitinib therapy for renal cancer in the native kidney after renal transplantation. The therapeutic efficacy and safety for such cases should be discussed.
収録刊行物
-
- BMC Research Notes
-
BMC Research Notes 7 (1), 526-, 2014-08-13
Springer Science and Business Media LLC